FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3180056052> ?p ?o ?g. }

• W3180056052 endingPage "175628482110233" @default.
• W3180056052 startingPage "175628482110233" @default.
• W3180056052 abstract "Prospectively and systematically collected real-world data on vedolizumab are scarce. We aimed to assess the long-term clinical effectiveness of vedolizumab in inflammatory bowel disease (IBD).This study was a prospective, observational, multicentre study. Overall, 286 patients with active IBD were included (Crohn's disease, n = 169; ulcerative colitis, n = 117). The primary outcomes were clinical response at week 12 and clinical remission at week 52, based on the Harvey Bradshaw Index and the partial Mayo Clinic score. Secondary outcomes included clinical remission at week 12, clinical response at week 52, corticosteroid-free clinical remission at week 52, changes in biochemical measures, and health-related quality of life (HRQoL).At baseline, 88% of the patients were exposed to anti-TNF and 41% of the patients with Crohn's disease had undergone ⩾1 surgical resection. At week 12, clinical response was 27% and remission 47% in Crohn's disease; corresponding figures in ulcerative colitis were 52% and 34%. Clinical response, remission and corticosteroid-free remission at week 52 were 22%, 41% and 40% in Crohn's disease and 49%, 47% and 46% in ulcerative colitis, respectively. A statistically significant decrease in median faecal-calprotectin and C-reactive protein was observed at 12 and 52 weeks in patients with Crohn's disease and ulcerative colitis. The HRQoL measures Short Health Scale and EuroQol 5-Dimensions improved in both Crohn's disease and ulcerative colitis patients (p < 0.001). Clinical disease activity at baseline was inversely associated with clinical remission at week 52.Vedolizumab proved effective for the treatment of refractory IBD in clinical practice." @default.
• W3180056052 created "2021-07-19" @default.
• W3180056052 creator A5002208020 @default.
• W3180056052 creator A5011546745 @default.
• W3180056052 creator A5016297911 @default.
• W3180056052 creator A5017335255 @default.
• W3180056052 creator A5018297605 @default.
• W3180056052 creator A5019252027 @default.
• W3180056052 creator A5019938824 @default.
• W3180056052 creator A5019960092 @default.
• W3180056052 creator A5024055027 @default.
• W3180056052 creator A5037425566 @default.
• W3180056052 creator A5057902086 @default.
• W3180056052 creator A5062458709 @default.
• W3180056052 creator A5068091489 @default.
• W3180056052 creator A5070381365 @default.
• W3180056052 creator A5073778265 @default.
• W3180056052 creator A5074870098 @default.
• W3180056052 creator A5087768306 @default.
• W3180056052 creator A5088819461 @default.
• W3180056052 creator A5091553385 @default.
• W3180056052 date "2021-01-01" @default.
• W3180056052 modified "2023-10-15" @default.
• W3180056052 title "Real-world effectiveness of vedolizumab in inflammatory bowel disease: week 52 results from the Swedish prospective multicentre SVEAH study" @default.
• W3180056052 cites W1147871078 @default.
• W3180056052 cites W2011837830 @default.
• W3180056052 cites W2013564592 @default.
• W3180056052 cites W2022661087 @default.
• W3180056052 cites W2031193040 @default.
• W3180056052 cites W2034795132 @default.
• W3180056052 cites W2077531651 @default.
• W3180056052 cites W2102013054 @default.
• W3180056052 cites W2118794829 @default.
• W3180056052 cites W2162805528 @default.
• W3180056052 cites W2215084273 @default.
• W3180056052 cites W2274605499 @default.
• W3180056052 cites W2321205867 @default.
• W3180056052 cites W2330470789 @default.
• W3180056052 cites W2427633307 @default.
• W3180056052 cites W2473786944 @default.
• W3180056052 cites W2498960570 @default.
• W3180056052 cites W2529617706 @default.
• W3180056052 cites W2545034339 @default.
• W3180056052 cites W2560112556 @default.
• W3180056052 cites W2586374020 @default.
• W3180056052 cites W2603062471 @default.
• W3180056052 cites W2623221337 @default.
• W3180056052 cites W2765680011 @default.
• W3180056052 cites W2778730693 @default.
• W3180056052 cites W2800857706 @default.
• W3180056052 cites W2804630856 @default.
• W3180056052 cites W2806806868 @default.
• W3180056052 cites W2809894743 @default.
• W3180056052 cites W2883309804 @default.
• W3180056052 cites W2885490300 @default.
• W3180056052 cites W2895702868 @default.
• W3180056052 cites W2914936826 @default.
• W3180056052 cites W2916794721 @default.
• W3180056052 cites W2948712291 @default.
• W3180056052 cites W3015082496 @default.
• W3180056052 cites W3041118237 @default.
• W3180056052 cites W3041424716 @default.
• W3180056052 cites W3047192447 @default.
• W3180056052 cites W3047915982 @default.
• W3180056052 doi "https://doi.org/10.1177/17562848211023386" @default.
• W3180056052 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8255566" @default.
• W3180056052 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34276808" @default.
• W3180056052 hasPublicationYear "2021" @default.
• W3180056052 type Work @default.
• W3180056052 sameAs 3180056052 @default.
• W3180056052 citedByCount "14" @default.
• W3180056052 countsByYear W31800560522022 @default.
• W3180056052 countsByYear W31800560522023 @default.
• W3180056052 crossrefType "journal-article" @default.
• W3180056052 hasAuthorship W3180056052A5002208020 @default.
• W3180056052 hasAuthorship W3180056052A5011546745 @default.
• W3180056052 hasAuthorship W3180056052A5016297911 @default.
• W3180056052 hasAuthorship W3180056052A5017335255 @default.
• W3180056052 hasAuthorship W3180056052A5018297605 @default.
• W3180056052 hasAuthorship W3180056052A5019252027 @default.
• W3180056052 hasAuthorship W3180056052A5019938824 @default.
• W3180056052 hasAuthorship W3180056052A5019960092 @default.
• W3180056052 hasAuthorship W3180056052A5024055027 @default.
• W3180056052 hasAuthorship W3180056052A5037425566 @default.
• W3180056052 hasAuthorship W3180056052A5057902086 @default.
• W3180056052 hasAuthorship W3180056052A5062458709 @default.
• W3180056052 hasAuthorship W3180056052A5068091489 @default.
• W3180056052 hasAuthorship W3180056052A5070381365 @default.
• W3180056052 hasAuthorship W3180056052A5073778265 @default.
• W3180056052 hasAuthorship W3180056052A5074870098 @default.
• W3180056052 hasAuthorship W3180056052A5087768306 @default.
• W3180056052 hasAuthorship W3180056052A5088819461 @default.
• W3180056052 hasAuthorship W3180056052A5091553385 @default.
• W3180056052 hasBestOaLocation W31800560521 @default.
• W3180056052 hasConcept C126322002 @default.
• W3180056052 hasConcept C188816634 @default.
• W3180056052 hasConcept C2776207728 @default.
• W3180056052 hasConcept C2778260677 @default.

• next